SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Version 1.3  Revision Date: 27.08.2021  SDS Number: 5723168-00004  Date of last issue: 09.04.2021
Date of first issue: 23.04.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Prednisolone / Chloramphenicol Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
Company: MSD
Kilsheean
Clonmel Tipperary, IE
Telephone: 353-51-601000
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Carcinogenicity, Category 2: H351: Suspected of causing cancer.
Reproductive toxicity, Category 1B: H360: May damage fertility or the unborn child.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)

Signal word: Danger
Hazard statements:
H351 Suspected of causing cancer.
H360 May damage fertility or the unborn child.

Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:
Chloramphenicol

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form combustible dust concentrations in air during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures
Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloramphenicol</td>
<td>56-75-7</td>
<td>200-287-4</td>
<td></td>
<td></td>
<td>Carc. 2; H351 Repr. 1B; H360</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>prednisolone</td>
<td>50-24-8</td>
<td>200-021-7</td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liver) Aquatic Chronic 2; H411</td>
<td>&gt;= 0.1 - &lt; 0.25</td>
</tr>
<tr>
<td>Basic phenylmercury nitrate</td>
<td>8003-05-2</td>
<td>080-008-00-9</td>
<td></td>
<td></td>
<td>Acute Tox. 3; H301 Skin Corr. 1; H314 Eye Dam. 1; H318 Repr. 1B; H360D STOT RE 1; H372 (Kidney) Aquatic Acute 1; H400 Aquatic Chronic 1;</td>
<td>&gt;= 0.0002 - &lt; 0.0025</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Version 1.3 Revision Date: 27.08.2021 SDS Number: 5723168-00004 Date of last issue: 09.04.2021

Date of first issue: 23.04.2020

H410 EUH071
M-Factor (Acute aquatic toxicity): 100
M-Factor (Chronic aquatic toxicity): 10

Acute toxicity estimate
Acute oral toxicity: 50.005 mg/kg

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of causing cancer.
May damage fertility or the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

**4.3 Indication of any immediate medical attention and special treatment needed**

**Treatment**: Treat symptomatically and supportively.

---

**SECTION 5: Firefighting measures**

**5.1 Extinguishing media**

Suitable extinguishing media: Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO2)  
Dry chemical

Unsuitable extinguishing media: None known.

**5.2 Special hazards arising from the substance or mixture**

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.  
Hazardous combustion products: Carbon oxides

**5.3 Advice for firefighters**

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

---

**SECTION 6: Accidental release measures**

**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions: Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not breathe vapours. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

### Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>OELV - 8 hrs (TWA) (particles)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA) (total (vapour and particles))</td>
<td>150 ppm 470 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>56-75-7</td>
<td>TWA</td>
<td>0.2 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Prednisolone</td>
<td>50-24-8</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>168 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>Hexadecan-1-ol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>220 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>220 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>125 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>125 mg/kg</td>
</tr>
</tbody>
</table>
Prednisolone / Chloramphenicol Formulation

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Fresh water</td>
<td>260 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>183 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>26 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>572 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>57.2 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>50 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Hexadecan-1-ol</td>
<td>Fresh water sediment</td>
<td>30 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>3 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>5.8 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Octadecan-1-ol</td>
<td>Fresh water sediment</td>
<td>56.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>5.66 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>11.3 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

**Eye protection**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**
- *Material*: Chemical-resistant gloves
- *Remarks*: Consider double gloving.

**Skin and body protection**
- *Work uniform or laboratory coat.*
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to I.S. EN 14387
- *Filter type*: Combined particulates and organic vapour type (A-P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

**Physical state**: cream
**Colour**: No data available
**Odour**: No data available
**Odour Threshold**: No data available
**Melting point/freezing point**: No data available
**Initial boiling point and boiling range**: No data available
**Flammability (solid, gas)**: May form combustible dust concentrations in air during processing, handling or other means.
**Flammability (liquids)**: Not applicable
**Upper explosion limit / Upper flammability limit**: No data available
**Lower explosion limit / Lower flammability limit**: No data available
**Flash point**: Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Auto-ignition temperature : No data available
Decomposition temperature : No data available
pH : No data available
Viscosity
  Viscosity, kinematic : Not applicable
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Vapour pressure : Not applicable
Relative density : No data available
Density : No data available
Relative vapour density : Not applicable

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : Not applicable
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : May form combustible dust concentrations in air during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Chloramphenicol:
Acute oral toxicity: LD50 Oral (Rat): 2,500 mg/kg

Prednisolone:
Acute oral toxicity: LD50 (Mouse): 1,680 mg/kg
LD50 (Rat): > 3,857 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available
Acute toxicity (other routes of administration):
LD50 (Rat): 147 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 767 mg/kg
Application Route: Intraperitoneal

Basic phenylmercury nitrate:
Acute oral toxicity: LD50 (Mouse): > 50 - 300 mg/kg
Remarks: Based on data from similar materials
Acute toxicity estimate: 50.005 mg/kg
Method: Calculation method

Acute inhalation toxicity: Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation
Not classified based on available information.

Components:

Prednisolone:
Prednisolone / Chloramphenicol Formulation

Remarks : No data available

Basic phenylmercury nitrate:
Result : Corrosive after 4 hours or less of exposure
Remarks : Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Chloramphenicol:
Remarks : Mild eye irritation

prednisolone:
Remarks : No data available

Basic phenylmercury nitrate:
Result : Irreversible effects on the eye
Remarks : Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
prednisolone:
Remarks : No data available

Germ cell mutagenicity
Not classified based on available information.

Components:
Chloramphenicol:
Genotoxicity in vitro : Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: mammalian cells
Result: positive

Genotoxicity in vivo
:  Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Result: positive

Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Result: negative

Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Result: negative

prednisolone:
Genotoxicity in vitro
:  Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo
:  Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Application Route: Oral
Result: negative

Test Type: sister chromatid exchange assay
Species: Humans
Result: negative

Carcinogenicity
Suspected of causing cancer.

Components:

Chloramphenicol:
Remarks
:  IARC: (International Agency for Research on Cancer)

Carcinogenicity - Assessment
:  Limited evidence of carcinogenicity in animal studies
Prednisolone / Chloramphenicol Formulation

**Reproductive toxicity**
May damage fertility or the unborn child.

**Components:**

**Chloramphenicol:**
Effects on foetal development:
- Species: Monkey, female
  - Result: No significant adverse effects were reported

Species: Mouse
  - Developmental Toxicity: LOAEL: 500 mg/kg body weight
  - Result: Embryo-foetal toxicity, Fetal growth retardation

Species: Rat
  - Developmental Toxicity: LOAEL: 500 - 2,000 mg/kg body weight
  - Result: Embryo-foetal toxicity, Fetal growth retardation, Teratogenic effects

Species: Rabbit
  - Developmental Toxicity: LOAEL: 1,000 mg/kg body weight
  - Result: Embryo-foetal toxicity, Fetal growth retardation

Reproductive toxicity - Assessment:
  - Clear evidence of adverse effects on sexual function and fertility, and/or on development, based on animal experiments

**Prednisolone:**
Effects on fertility:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Subcutaneous
  - Fertility: NOAEL: 1 mg/kg body weight
  - Result: No effects on fertility

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 0.5 mg/kg body weight
  - Result: Malformations were observed, Cleft palate

Test Type: Embryo-foetal development
- Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 30 mg/kg body weight
  - Result: decreased blood formation

Species: Rat
  - Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 25 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Basic phenylmercury nitrate:
Effects on foetal development:
Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive
Remarks: Based on data from similar materials

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:

Chloramphenicol:
Exposure routes: Oral
Target Organs: Blood, Bone marrow

STOT - repeated exposure
Not classified based on available information.

Components:

Chloramphenicol:
Exposure routes: Oral, Inhalation
Target Organs: Blood, Bone marrow, Liver

Prednisolone:
Target Organs: Bone marrow, Adrenal gland, Liver
Assessment: Causes damage to organs through prolonged or repeated exposure.

Basic phenylmercury nitrate:
Exposure routes: Oral
Target Organs: Kidney
Assessment: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Chloramphenicol:
Species: Dog
**Prednisolone / Chloramphenicol Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3</td>
<td>27.08.2021</td>
<td>5723168-00004</td>
<td>09.04.2021</td>
<td>23.04.2020</td>
</tr>
</tbody>
</table>

**Target Organs**

**Blood, Bone marrow**

**Symptoms**

-decrease in appetite, Reduced body weight

### Prednisolone:

**Species**

-Rat

**LOAEL**

-0.6 mg/kg

**Application Route**

-Oral

**Exposure time**

-63 Days

**Target Organs**

-Bone marrow

**Species**

-Dog

**LOAEL**

-2.5 mg/kg

**Application Route**

-Oral

**Exposure time**

-6 Weeks

**Target Organs**

-Adrenal gland

**Species**

-Rabbit

**LOAEL**

-1 mg/kg

**Application Route**

-Oral

**Exposure time**

-24 Weeks

**Target Organs**

-Liver

### Basic phenyldmercury nitrate:

**Species**

-Rat

**NOAEL**

-< 1.25 mg/kg

**Application Route**

-Ingestion

**Exposure time**

-2 yr

**Remarks**

-Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

### 11.2 Information on other hazards

#### Endocrine disrupting properties

**Product:**

**Assessment**

-The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

**Components:**

**Chloramphenicol:**

**General Information**

-Target Organs: Blood
-Target Organs: Bone marrow
-Symptoms: aplastic anemia, confusion, Diarrhoea, Fever, Headache, Nausea, Vomiting
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Version 1.3 Revision Date: 27.08.2021 SDS Number: 5723168-00004 Date of last issue: 09.04.2021
Date of first issue: 23.04.2020

prednisolone:
Ingestion
Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

SECTION 12: Ecological information

12.1 Toxicity

Components:

prednisolone:
Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 85 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants
NOEC (Pseudokirchneriella subcapitata (green algae)): 160 mg/l
Exposure time: 72 h
EC50 (Pseudokirchneriella subcapitata (green algae)): > 160 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
NOEC: 0.23 mg/l
Exposure time: 7 d
Species: Ceriodaphnia dubia (water flea)

Basic phenylmercury nitrate:
Toxicity to fish
EC50 (Oncorhynchus mykiss (rainbow trout)): > 0.001 - 0.01 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 0.001 - 0.01 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants
ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.01 - 0.1 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials
EC10 (Pseudokirchneriella subcapitata (green algae)): > 0.01 - 0.1 mg/l
Exposure time: 72 h
Remarks: Based on data from similar materials

M-Factor (Acute aquatic toxicity)
100

Toxicity to microorganisms
NOEC (Bacteria): > 0.001 - 0.01 mg/l
Exposure time: 18 h
Remarks: Based on data from similar materials
12.2 Persistence and degradability

**Components:**

**Basic phenylmercury nitrate:**
Biodegradability: Result: Readily biodegradable.
Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

**Components:**

**prednisolone:**
Partition coefficient: n-octanol/water: $\log Pow: 1.46$

**Basic phenylmercury nitrate:**
Partition coefficient: n-octanol/water: $\log Pow: 1.27$

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Conditions of restriction for the following entries should be considered: Basic phenylmercury nitrate (Number on list 18)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59), Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Version 1.3  Revision Date: 27.08.2021  SDS Number: 5723168-00004  Date of last issue: 09.04.2021
Date of first issue: 23.04.2020

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
REACH - List of substances subject to authorisation (Annex XIV)
Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements
H301 : Toxic if swallowed.
H302 : Harmful if swallowed.
H314 : Causes severe skin burns and eye damage.
H318 : Causes serious eye damage.
H351 : Suspected of causing cancer.
H360 : May damage fertility or the unborn child.
H360D : May damage the unborn child.
H361d : Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H411 : Toxic to aquatic life with long lasting effects.
EUH071 : Corrosive to the respiratory tract.

Full text of other abbreviations
Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Carc. : Carcinogenicity
Eye Dam. : Serious eye damage
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Prednisolone / Chloramphenicol Formulation

Version: 1.3  Revision Date: 27.08.2021  SDS Number: 5723168-00004  Date of last issue: 09.04.2021

Date of first issue: 23.04.2020

Repr. : Reproductive toxicity
Skin Corr. : Skin corrosion
STOT RE : Specific target organ toxicity - repeated exposure
IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - Quantitative Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Taiwan Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information


Classification of the mixture:

<table>
<thead>
<tr>
<th>Carc. 2</th>
<th>H351</th>
<th>Calculation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repr. 1B</td>
<td>H360</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be
considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN